This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Narayanan, B. A. Articles by Reddy, B. S. Search for Related Content PubMed PubMed Citation Articles by Narayanan, B. A. Articles by Reddy, B. S.

Regression of Mouse Prostatic Intraepithelial Neoplasia by Nonsteroidal Anti-inflammatory Drugs in the Transgenic Adenocarcinoma Mouse Prostate Model

¹ Cancer Genomics Laboratory, ² Chemoprevention and Nutritional Carcinogenesis Program, and ³ Statistics and Data Management, Institute for Cancer Prevention, Valhalla, New York

Purpose: Epidemiologic studies have revealed a decreased risk of colon cancer among people who have regularly taken cyclooxygenase (COX)-2 inhibitors such as aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). Whereas the selective COX-2 inhibitor celecoxib and exisulind, a metabolic product of sulindac, have gained increasing attention as efficacious chemopreventive agents against colon and prostate cancer, not much is known about the underlying molecular targets and mechanisms. Moreover, the side effects of NSAIDs are a major obstacle for large-scale application to the prevention of cancer in humans; for example, in the United States in 1998, there were 16,550 deaths from NSAID-induced gastrointestinal complications. The toxicity associated with these compounds is raising concerns, and more needs to be known about their mode of action and molecular targets.

Experimental Design: We used the transgenic mouse prostate (TRAMP) model, which exhibits similarities with human prostate cancer, including epithelial origin, progression from the PIN stage to adenocarcinoma, and metastasis by a transgene that is hormonally regulated by androgens. In addition to histologically analyzing the PIN lesions of the dorsolateral prostate from TRAMP mice, we delineated the molecular targets and mechanisms of celecoxib and exisulind against mouse PIN lesions. We performed Western blot analysis of the total protein lysate from the tissues of mouse PIN lesions to measure the level of expression of androgen receptor, vascular endothelial growth factor, nuclear factor-B p65, BclII, AKT (total and phosphorylated Ser⁴⁷³), p53, cyclin-dependent kinase inhibitor p21^WAF1/CIP1, p27, BAX, and caspase-3 to demonstrate the COX-2–independent mechanism involved in the inhibition of PIN lesions of the dorsolateral prostate by both celecoxib and exisulind.

Results: We found for the first time that (a) both celecoxib and exisulind as dietary supplements induce strong inhibitory effects against prostate cancer at doses of 800 and 500 ppm, respectively, after 16 weeks; (b) the histologic analysis of the dorsolateral prostate after 2 weeks of treatment indicated a reduction of PIN lesions from 75% to 19% with celecoxib and to 16% with exisulind; (c) more importantly, those few PINs and adenocarcinomas in the groups treated with celecoxib or exisulind showed more apoptotic cells, lower levels of proliferating cell nuclear antigen, and a lower number of mitotic cells. To understand the molecular mechanisms involved in the inhibition of PIN lesions, first, we examined the expression of molecular targets involved in angiogenesis and inflammatory processes. It was clearly evident from Western blot analysis of the total protein lysate derived from the dorsolateral prostate tissues with PIN lesions that expression of androgen receptor, vascular endothelial growth factor, nuclear factor-B p65, and BclII is down-regulated more effectively by celecoxib. Down-regulation of AKT protein (total and phosphorylated at Ser⁴⁷³) signaling by celecoxib clearly indicates an inhibition of the survival gene and the pathological process that could otherwise lead to adenocarcinoma.

Conclusions: Overall, the findings from this study clearly show the effectiveness of celecoxib and exisulind in reducing the PIN lesions by modulating a cascade of molecular targets involved in COX-2–dependent and –independent mechanisms. Whereas these agents are already in clinical trial or in use as chemopreventive agents, findings from this study demonstrate the difference in their mode of action, thus helping us to understand the side effects.

This article has been cited by other articles:

				F. Di Cello, J. Hillion, J. Kowalski, B. M. Ronnett, A. Aderinto, D. L. Huso, and L. M.S. Resar Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts Mol. Cancer Ther., July 1, 2008; 7(7): 2090 - 2095. [Abstract] [Full Text] [PDF]

				H. Guillen-Ahlers, S. A. Buechler, M. A. Suckow, F. J. Castellino, and V. A. Ploplis Sulindac treatment alters collagen and matrilysin expression in adenomas of ApcMin/+ mice Carcinogenesis, July 1, 2008; 29(7): 1421 - 1427. [Abstract] [Full Text] [PDF]

				X. Wang, J. K.L. Colby, P. Yang, S. M. Fischer, R. A. Newman, and R. D. Klein The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue Carcinogenesis, January 1, 2008; 29(1): 120 - 128. [Abstract] [Full Text] [PDF]

				B. A. Narayanan, B. S. Reddy, M. C. Bosland, D. Nargi, L. Horton, C. Randolph, and N. K. Narayanan Exisulind in Combination with Celecoxib Modulates Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Cyclin D1 against Prostate Carcinogenesis: In vivo Evidence Clin. Cancer Res., October 1, 2007; 13(19): 5965 - 5973. [Abstract] [Full Text] [PDF]

				X. Zheng, X.-X. Cui, G. E. Avila, M.-T. Huang, Y. Liu, J. Patel, A. N. T. Kong, R. Paulino, W. J. Shih, Y. Lin, et al. Atorvastatin and Celecoxib Inhibit Prostate PC-3 Tumors in Immunodeficient Mice Clin. Cancer Res., September 15, 2007; 13(18): 5480 - 5487. [Abstract] [Full Text] [PDF]

				H. Funahashi, M. Satake, D. Dawson, N.-A. Huynh, H. A. Reber, O. J. Hines, and G. Eibl Delayed Progression of Pancreatic Intraepithelial Neoplasia in a Conditional KrasG12D Mouse Model by a Selective Cyclooxygenase-2 Inhibitor Cancer Res., August 1, 2007; 67(15): 7068 - 7071. [Abstract] [Full Text] [PDF]

				A. C-K. Chung, S. Zhou, L. Liao, J. C.-Y. Tien, N. M. Greenberg, and J. Xu Genetic Ablation of the Amplified-in-Breast Cancer 1 Inhibits Spontaneous Prostate Cancer Progression in Mice Cancer Res., June 15, 2007; 67(12): 5965 - 5975. [Abstract] [Full Text] [PDF]

				A. M. Sargeant, R. D. Klein, R. C. Rengel, S. K. Clinton, S. K. Kulp, Y. Kashida, M. Yamaguchi, X. Wang, and C.-S. Chen Chemopreventive and Bioenergetic Signaling Effects of PDK1/Akt Pathway Inhibition in a Transgenic Mouse Model of Prostate Cancer Toxicol Pathol, June 1, 2007; 35(4): 549 - 561. [Abstract] [Full Text] [PDF]

				V. M. Adhami, A. Malik, N. Zaman, S. Sarfaraz, I. A. Siddiqui, D. N. Syed, F. Afaq, F. S. Pasha, M. Saleem, and H. Mukhtar Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both In vitro and In vivo Clin. Cancer Res., March 1, 2007; 13(5): 1611 - 1619. [Abstract] [Full Text] [PDF]

				C. Van Waes Nuclear Factor-{kappa}B in Development, Prevention, and Therapy of Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1076 - 1082. [Abstract] [Full Text] [PDF]

				L. F. Zerbini, A. Czibere, Y. Wang, R. G. Correa, H. Otu, M. Joseph, Y. Takayasu, M. Silver, X. Gu, K. Ruchusatsawat, et al. A Novel Pathway Involving Melanoma Differentiation Associated Gene-7/Interleukin-24 Mediates Nonsteroidal Anti-inflammatory Drug-Induced Apoptosis and Growth Arrest of Cancer Cells Cancer Res., December 15, 2006; 66(24): 11922 - 11931. [Abstract] [Full Text] [PDF]

				N. Kobayashi, R. J. Barnard, S. M. Henning, D. Elashoff, S. T. Reddy, P. Cohen, P. Leung, J. Hong-Gonzalez, S. J. Freedland, J. Said, et al. Effect of Altering Dietary {omega}-6/{omega}-3 Fatty Acid Ratios on Prostate Cancer Membrane Composition, Cyclooxygenase-2, and Prostaglandin E2 Clin. Cancer Res., August 1, 2006; 12(15): 4662 - 4670. [Abstract] [Full Text] [PDF]

				B. A. Narayanan, N. K. Narayanan, L. Davis, and D. Nargi RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor Mol. Cancer Ther., May 1, 2006; 5(5): 1117 - 1125. [Abstract] [Full Text] [PDF]

				M. Mimeault and S. K. Batra Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies Carcinogenesis, January 1, 2006; 27(1): 1 - 22. [Abstract] [Full Text] [PDF]

				J. Moreno, A. V. Krishnan, S. Swami, L. Nonn, D. M. Peehl, and D. Feldman Regulation of Prostaglandin Metabolism by Calcitriol Attenuates Growth Stimulation in Prostate Cancer Cells Cancer Res., September 1, 2005; 65(17): 7917 - 7925. [Abstract] [Full Text] [PDF]